Moteur de recherche d’entreprises européennes
Financement de l’UE (3 894 543 €) : Nanomédecine : une approche intégrative Hor 27/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Nanomédecine : une approche intégrative
Nanomedicine (NM) is regarded as one of the most promising applications of nanotechnology, as it would allow the development of tailored therapies, with a high level of selectivity and efficacy. Although much research has been performed over the past decades, translation from academia to commercial application remains disappointingly low. Reasons that explain the current moderate success of NM are: (1) promising preclinical results are often poorly predictive for clinical safety and effectiveness, (2) the efficient, scalable and reproducible GMP production of nanocarriers has proven to be challenging and (3) regulatory frameworks are not yet fully equipped to efficiently facilitate the introduction of novel nanomedicines. These obstacles are often encountered since the developmental process from carrier design to clinical assessment is performed by a range of scientists from different backgrounds who have difficulty interacting and communicating with each other to clearly understand the necessary design criteria and the scope and limitations of NM. NANOMED brings together all the necessary expertise to oversee the entire development trajectory required for NM. This is achieved by the combined effort of 7 beneficiaries from academia and industry and 5 non-academic partner organisations, which are all thoroughly rooted in nanosciences and pharmaceutical sciences. Our objective is to develop scalable and highly controllable design and synthesis methods for the most promising nanomedicine types in a preclinical setting. NANOMED will train the next generation of NM scientists by offering an extensive joint training programme to 15 incoming ESRs. It focuses on promoting scientific excellence and exploits the specific research and commercial expertise and infrastructure of the NANOMED network as a whole. The exposure to all elements of NM design enables NANOMED to translate expertise from all disciplines to the ESRs, to educate the future leading scientists in the NM field.
| Byondis B.V. | ? |
| Chemconnection B.V. | 255 374 € |
| Helsingin Yliopisto | 538 291 € |
| Imperial College of Science Technology and Medicine | 546 576 € |
| Stichting Radboud Universiteit | 113 500 € |
| Technische Universiteit Eindhoven | 652 623 € |
| Universite de Bordeaux | 525 751 € |
| Universiteit Gent | 751 680 € |
| Universiteit Utrecht | 510 749 € |
https://cordis.europa.eu/project/id/676137
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Byondis B.V., Nijmegen, Pays-Bas.